Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database

Read full text Summarise with VIRAT
Authors: Connor Frey
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BackgroundFutibatinib, a novel FGFR inhibitor, is a promising therapy for cancers with FGFR alterations. However, its safety profile remains under investigation. This study evaluates futibatinib-associated adverse events using the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis was conducted using FAERS data from January 1, 2013, to March 9, 2025. Disproportionality analysis was performed via OpenVigil 2.1, with signals defined by a reporting odds ratio (ROR) > 2.00 and a 95% confidence interval lower bound >1.00. Events with at least two reports were included after deduplication and standardization.ResultsStrong safety signals were identified. Hyperphosphatasemia showed the highest association (ROR 1612.73; 6 events), followed by elevated blood phosphorus (ROR 603.85; 3 events). Dermatologic toxicities, including onycholysis (ROR 520.15) and onychoclasis (ROR 126.20), were also notable.ConclusionThese findings highlight the range of adverse events associated with this agent. These events may reflect direct drug effects and individual variability. Further studies are needed to clarify mechanisms and inform clinical management.

Fields of Study & Subjects

Pharmacovigilance and Adverse Drug Reactions Statistical Methods in Clinical Trials Fibroblast Growth Factor Research

Publication details

Journal / source
Journal of Oncology Pharmacy Practice
Pages
10781552261433918–10781552261433918
Publication date
21 March 2026
Language
EN